A. V. Fateeva
A5065136898- COVID-19 Clinical Research Studies
- Advanced Breast Cancer Therapies
- Healthcare Systems and Public Health
- COVID-19 and healthcare impacts
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Biosimilars and Bioanalytical Methods
- Colorectal Cancer Treatments and Studies
- Infection Control and Ventilation
- Cancer survivorship and care
- PI3K/AKT/mTOR signaling in cancer
- Medical and Agricultural Research Studies
- Economic and Financial Impacts of Cancer
- Effects of Radiation Exposure
- Advances in Oncology and Radiotherapy
North-Eastern Federal University
2025
State Healthcare Institution "Regional Clinical Oncological Dispensary"
2020-2022
Far Eastern Federal University
2021
The article presents data from a retrospective study of COVID-19 outcomes in cancer patients 24 regions the Russian Federation. included 1,055 who had Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. mean age was 58.7 years (29–90); 108 (10.2 were diagnosed with various comorbidities. 627 (59.4 receiving antitumor drug therapy at time diagnosis COVID-19, 332 (31.5 received chemotherapy. Most asymptomatic or mild COVID-19: 205 (19.4 patients, — 517 (49.0 patients....
In the end of year 2019 there was an outbreak new coronavirus infection with epicenter in China, Wuhan (Hubei province). On 11th February WHO defined official name generated by – COVID-19 (COronaVIrus Disease 2019). International Committee on Virus Taxonomy assigned to causative agent SARS-CoV-2. The emergence set task medical specialists connected fast diagnostics and providing treatment patients. Currently intensive study clinical epidemiological peculiarities disease, development ways...
Background. By 2020, breast cancer (BC) has become the most frequent malignancy in world. The common type of BC is HR+/HER2-negative cancer,2540% which harbors PIK3CA mutations that affect catalytic subunit PI3K protein. alterations are actionable, as such neoplasms can be treated with a combination fulvestrant and inhibitor alpelisib. As have an extremely versatile effect on characteristics tumor cell, numerous associations various clinico-pathological traced.
 Aim. Our aim was to...
Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) biosimilar produced by “Biocad” (Avegra) in patients metastatic colon cancer. Materials methods. This retrospective observational study included cancer treated 9 clinics Russian Federation. Inclusion criteria were as follows: or locally advanced therapy (Avastin Avegra). The primary outcome measure was overall survival (OS). Secondary measures progression‑free (PFS), disease...